BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 12530050)

  • 1. Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity.
    Kern W; Braess J; Kotschofsky M; Samel S; Becker H; Hiddemann W; Schleyer E
    Anticancer Res; 2002; 22(5):3099-102. PubMed ID: 12530050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microalbuminuria during cisplatin therapy: relation with pharmacokinetics and implications for nephroprotection.
    Kern W; Braess J; Kaufmann CC; Wilde S; Schleyer E; Hiddemann W
    Anticancer Res; 2000; 20(5C):3679-88. PubMed ID: 11268439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma.
    Mok TS; Kanekal S; Lin XR; Leung TW; Chan AT; Yeo W; Yu S; Chak K; Leavitt R; Johnson P
    Cancer; 2001 Jun; 91(12):2369-77. PubMed ID: 11413527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis.
    Bartlett DL; Buell JF; Libutti SK; Reed E; Lee KB; Figg WD; Venzon DJ; Alexander HR
    Cancer; 1998 Sep; 83(6):1251-61. PubMed ID: 9740093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy.
    Panteix G; Beaujard A; Garbit F; Chaduiron-Faye C; Guillaumont M; Gilly F; Baltassat P; Bressolle F
    Anticancer Res; 2002; 22(2B):1329-36. PubMed ID: 12168946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Problems with intraoperative hyperthermic peritoneal chemotherapy for advanced gastric cancer.
    Samel S; Singal A; Becker H; Post S
    Eur J Surg Oncol; 2000 Apr; 26(3):222-6. PubMed ID: 10753533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of cis-diamminedichloroplatinum (II) given as low-dose and high-dose infusions.
    Kurihara N; Kubota T; Hoshiya Y; Otani Y; Ando N; Kumai K; Kitajima M
    J Surg Oncol; 1996 Jun; 62(2):135-8. PubMed ID: 8649040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study.
    Stathopoulos GP; Boulikas T; Vougiouka M; Deliconstantinos G; Rigatos S; Darli E; Viliotou V; Stathopoulos JG
    Oncol Rep; 2005 Apr; 13(4):589-95. PubMed ID: 15756428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacokinetic study of intraperitoneal chemotherapy with high-dose cisplatin for advanced ovarian cancer].
    Deng C; Huang R; Lian L
    Zhonghua Fu Chan Ke Za Zhi; 1996 Mar; 31(3):159-62. PubMed ID: 8758790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of intraoperative hypotonic peritoneal chemo-hyperthermia combined with early postoperative intraperitoneal chemotherapy on gastric cancer].
    Wei G; Fang GE; Bi JW; Shen XJ; Nie MM; Xue XC; Hua JD
    Ai Zheng; 2005 Apr; 24(4):478-82. PubMed ID: 15820074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic outcomes of continuous hyperthermic peritoneal perfusion against advanced gastric cancer with peritoneal carcinomatosis.
    Kunisaki C; Shimada H; Akiyama H; Nomura M; Matsuda G; Otsuka Y; Ono H; Takahashi M
    Hepatogastroenterology; 2006; 53(69):473-8. PubMed ID: 16795995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study.
    Jehn CF; Boulikas T; Kourvetaris A; Possinger K; Lüftner D
    Anticancer Res; 2007; 27(1A):471-5. PubMed ID: 17352269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics and pharmacodynamics of cisplatinum during hyperthermic intraperitoneal chemotherapy using a closed abdominal procedure.
    Cotte E; Colomban O; Guitton J; Tranchand B; Bakrin N; Gilly FN; Glehen O; Tod M
    J Clin Pharmacol; 2011 Jan; 51(1):9-18. PubMed ID: 20173087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of cisplatin after intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC).
    Zeamari S; Floot B; van der Vange N; Stewart FA
    Anticancer Res; 2003; 23(2B):1643-8. PubMed ID: 12820435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
    Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
    Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal chemotherapy: a single western center experience.
    Scaringi S; Kianmanesh R; Sabate JM; Facchiano E; Jouet P; Coffin B; Parmentier G; Hay JM; Flamant Y; Msika S
    Eur J Surg Oncol; 2008 Nov; 34(11):1246-52. PubMed ID: 18222622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients.
    Erdlenbruch B; Nier M; Kern W; Hiddemann W; Pekrun A; Lakomek M
    Eur J Clin Pharmacol; 2001 Aug; 57(5):393-402. PubMed ID: 11599657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot.
    van der Vange N; van Goethem AR; Zoetmulder FA; Kaag MM; van de Vaart PJ; ten Bokkel Huinink WW; Beijnen JH
    Eur J Surg Oncol; 2000 Nov; 26(7):663-8. PubMed ID: 11078613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma.
    Richards WG; Zellos L; Bueno R; Jaklitsch MT; Jänne PA; Chirieac LR; Yeap BY; Dekkers RJ; Hartigan PM; Capalbo L; Sugarbaker DJ
    J Clin Oncol; 2006 Apr; 24(10):1561-7. PubMed ID: 16575008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacokinetic analysis of intra-peritoneal administration of cisplatin].
    Terashima M; Ikeda K; Takagane A; Sasaki N; Abe K; Araya M; Nishizuka S; Yonezawa H; Irinoda T; Nakaya T; Oyama K; Saito K
    Gan To Kagaku Ryoho; 1997 Sep; 24(12):1859-62. PubMed ID: 9382551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.